Chris O’Brien Lifehouse

Hospital


Location: Sydney, Australia (AU) AU

ISNI: -

ROR: https://ror.org/00qeks103

Show on Map:

close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC (2026) Girard N, Bar J, Baas P, Chouaid C, Christoph DC, Field JK, Fietkau R, et al. Journal article Radiotherapy patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients with unresectable stage III non-small-cell lung cancer treated with durvalumab after chemoradiotherapy (2026) Filippi AR, Bar J, Christoph DC, Field JK, Fietkau R, Garassino MC, Garrido P, et al. Journal article 3D In Vitro Glioma-Neuron-Astrocyte Biomimetic Composites Recapitulate Key Molecular Mechanisms Linked to Glioblastoma Multiforme Pathophysiology (2025) Mier MS, Türker E, Faber J, Friedrich M, Lamberger Z, Weigelt J, Suwannakot P, et al. Journal article Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R (2024) Filippi AR, Bar J, Chouaid C, Christoph DC, Field JK, Fietkau R, Garassino MC, et al. Journal article Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial (2023) Koch R, Haveman L, Ladenstein R, Brichard B, Jürgens H, Cyprova S, van den Berg H, et al. Journal article High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma (2022) Koch R, Gelderblom H, Haveman L, Brichard B, Jürgens H, Cyprova S, Van Den Berg H, et al. Journal article PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy (2021) Girard N, Smit HJM, Sibille A, Mcdonald F, Mornex F, Garassino MCC, Filippi AR, et al. Conference contribution